Evicenter
MarkdownMedical informationP&T meetings
Ifezuntirgene inilparvovec (AMT-130)

Huntington's disease

Manufacturer
uniQure
Launch
Not announced
Last updated
291 sources

Executive summary

Burden of Huntington's disease

5 evidence topics · 39 sources

Summary: definition, epidemiology, natural history, and mortality

Huntington's disease (HD) is an autosomal dominant, progressive disorder of motor, cognitive, and psychiatric manifestations caused by an expanded CAG trinucleotide repeat in HTT, the gene that encodes huntingtin. Offspring of an individual with the expansion have a 50% chance of inheriting it. Penetrance is variable for alleles carrying 36-39 repeats, and the disease appears fully penetrant when the repeat numbers are >40.

  • Incidence: pooling 33 studies published between 2010 and 2022 reported a pooled incidence of 0.48 cases per 100,000 person-years (95% CI, 0.33-0.63). In an insurance database cohort of 3,707 individuals diagnosed between 2003 and 2016, the cumulative incidence rate was 1.22 per 100,000 person years. In the Medicare population, 819 incident cases were identified in 2017, an incidence rate of 6.1 per 100,000 person-years.
  • Prevalence: the pooled prevalence was 4.88 per 100,000 (95% CI, 3.38-7.06). In populations of European ancestry, the average prevalence is 9.71 per 100,000, with up to 17 per 100,000 when multiple sources of ascertainment are accounted for. The prevalence proportion was 13.1 per 100,000 in the Medicare population in 2017 and 15.2 per 100,000 in the Medicaid population in 2014. The Huntington's Disease Society of America states that approximately 41,000 Americans are symptomatic and more than 200,000 are at risk of inheriting the disease; the sponsor states that approximately 75,000 people have HD in the U.S., EU, and UK, with approximately 40,000 symptomatic patients in the U.S.
  • Natural history: the mean age of onset is approximately 45 years, and subtle changes can occur as early as 15-20 years before clinical onset. In approximately 25% of individuals, onset is delayed until after age 50 years. The proportion with juvenile HD, defined by onset of symptoms before age 20 years, varies from 1% to 15% of individuals diagnosed with HD. In 960 participants with definite HD followed prospectively for a mean of 18.3 months, the Total Functional Capacity (TFC) score declined at 0.72 units/year (SE 0.04). The median survival time after onset is 15 to 18 years (range: 5 to >25 years), and the average age at death is 54 to 58 years.
  • Mortality: in one cohort, individuals with HD had a hazard ratio for death of 4.51 (95% CI 3.36–6.06) relative to controls after multivariable adjustment, with a median age at death of 71 years compared with 81 years in controls. In one study, the mean age at death was 63.9 years (NCDR) and 61.7 years (CRD) compared with 76.9 years in the general population; HD was the underlying cause of death in 73.5% of individuals, respiratory diseases were the most common immediate cause (44.2%), and suicide accounted for 2.3% of deaths compared with 1.3% in the general population. In a chart review, 86.8% of patients whose cause of death could be identified died from aspiration pneumonia.
Summary: symptoms and long-term morbidity
  • Motor: chorea is the major sign of HD and is present in most individuals. With advancing disease, chorea may decrease and bradykinesia, rigidity, and dystonia occur; oculomotor disturbances occur in up to 75% of symptomatic individuals.
  • Cognitive: a global and progressive decline in cognitive capabilities occurs in all individuals with HD, often beginning with loss of mental flexibility and impairment of executive functions.
  • Psychiatric: depression affects 40% of individuals with HD. In one study, ninety-eight per cent of patients exhibited neuropsychiatric symptoms, most commonly dysphoria, agitation, irritability, apathy, and anxiety. Apathy was present in 32% of preHD-A participants and 62% of early-HD patients.
  • Other: swallowing difficulties can lead to choking episodes and aspiration pneumonia, and individuals with HD tend to experience substantial weight loss.
  • Morbidity: in late stages, the individual is often totally dependent, mute, and incontinent. In one study, 27 participants (60%) reported two or more falls in the previous year. Among 3,070 individuals with clinically definite HD, 228 (7.4%) resided in skilled nursing facilities, and bradykinesia, impaired gait, and impaired tandem walking predicted placement. Across studies, depression (median r=0.48) and apathy (median r=0.47) were the symptoms most commonly associated with decreased functional capacity.
Summary: humanistic burden
  • In a study of 2,094 people with HD, the mean EQ-5D-5L utility score (n = 336) was 0.59 (SD, 0.27), with mean scores of 0.72 in early stage, 0.62 in middle stage, and 0.37 in advanced stage disease; the mean SF-6D score (n = 482) was 0.57. Current suicidal ideation was reported by 13% and previous suicidal ideation by 28% of participants, and 91% of 482 questionnaire respondents reported difficulty sleeping.
  • A review of 383 screened articles, covering 11 distinct studies, reported an EQ-5D index range of 0.89 - 0.72 for mild or prodromal HD and 0.71 - 0.37 for severe or late-stage disease, with high variability in published estimates.
  • In a study of 84 participants, mean HRQoL values were 0.84 in the early phase, 0.74 in the middle phase, and 0.65 in the advanced phase.
  • In a survey, individuals with HD had a mean EQ-5D of 0.66 compared with 0.81 in the general population cohort, and 51.2% had comorbid anxiety.
  • In time trade-off valuations of chorea health states, utility values were 0.07 for severe chorea and 0.64 for mild chorea.
  • Functional capacity and depressive mood were significantly associated with health-related quality of life; motor symptoms and cognitive function were less closely linked.
Summary: economic burden
  • In a study of 3,688 matched pairs of beneficiaries with and without HD, mean annual total healthcare costs were $41,631 with HD and $17,222 without, driven primarily by outpatient pharmacy costs; by stage, mean costs were $20,475 in early-stage, $29,733 in middle-stage, and $56,657 in late-stage HD.
  • In a matched study of 595 beneficiaries with HD and 1,785 without, mean annual total costs were $73,087 and $26,834, respectively, driven by inpatient costs; costs were $95,251 in late-stage HD.
  • In commercial and Medicaid claims data from 1272 individuals with HD, the mean total annualized cost per patient increased by stage (commercial: $4947 to $22,582; Medicaid: $3257 to $37,495), and 73.8% of Medicaid late-stage patients received nursing home care.
  • In another study, mean total costs (2018 USD per patient per month) were $2,260 for individuals with HD and $1,056 for matched non-HD controls.
  • In the HDBOI study (2020 euros), cost estimates were €12,663 for direct medical costs, €2984 for nondirect medical costs, and €47,576 for indirect costs; total costs were €62,372, ranging from €42,477 in early stage to €86,177 in advanced stage. Indirect costs accounted for 84%, 80%, and 66% of early, middle, and advanced stage total costs. In the USA, direct medical costs were €27,743 and indirect costs were €74,228.
  • In one cohort, 89.8% of patients with a TFC score of 7–10 were unemployed, and fewer than 20% remained employed 4 years after clinical diagnosis.
Summary: caregiver and family burden
  • In the UK, the mean annual cost per person with HD was £21,605, of which 65% (£14,085) was due to informal care, and informal care was the largest cost driver across all stages. In another study, informal care costs (€30,605 over six months) accounted for approximately half of total societal costs. A synthesis of five cost studies reported annual caregiver costs ranging from $6041 in early stage to $133,200 in late-stage HD.
  • In one caregiver survey, respondents reported an average of 34 hours of informal care per week; 37 (7%) had stopped working because of caregiving and 206 (41%) reported an impact on their career. Impairment in caregiver daily activities was 42%, 48%, and 52% for early, middle, and advanced stage disease.
  • In one study, 80 informal caregivers provided a mean of 7.3 hours of informal care per day. In another, 55.3% of care partners experienced high strain. In a survey, depression was reported by 65.0% of HD care partners compared with 19.6% of general population care partners.
  • Higher caregiver burden was associated with total functional capacity and being the sole caregiver in one study, and with a more severe Shoulson-Fahn stage in another. Stakeholder input to ICER states that 24/7 care is eventually needed, particularly during the last five years of life.
  • Across the United States, Canada, and Australia, 46.2% of surveyed respondents reported genetic discrimination or stigma, including 25.9% in the domain of insurance.